PI Global Investments
Hedge Funds

New York State Common Retirement Fund Grows Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)


New York State Common Retirement Fund boosted its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYELGet Rating) by 683.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 108,904 shares of the company’s stock after purchasing an additional 95,000 shares during the period. New York State Common Retirement Fund’s holdings in Lyell Immunopharma were worth $550,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Qube Research & Technologies Ltd purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $87,000. ProShare Advisors LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $302,000. CIBC Asset Management Inc purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $81,000. BBR Partners LLC purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $1,270,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Lyell Immunopharma in the fourth quarter valued at about $222,000. 44.80% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Trading Down 4.3 %

NASDAQ:LYEL opened at $7.04 on Friday. The company has a market capitalization of $1.74 billion, a P/E ratio of -8.69 and a beta of -1.97. Lyell Immunopharma, Inc. has a 12 month low of $3.57 and a 12 month high of $19.84. The business’s 50-day moving average is $6.23 and its 200 day moving average is $5.72.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group lowered their price objective on Lyell Immunopharma from $21.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday, May 24th.

About Lyell Immunopharma

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.

Read More

Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. (NASDAQ:LYELGet Rating).

Institutional Ownership by Quarter for Lyell Immunopharma (NASDAQ:LYEL)



Receive News & Ratings for Lyell Immunopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lyell Immunopharma and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related posts

Eqonex expands senior leadership team

Miles

These 10 stocks matter the most to hedge funds right now

Miles

Two CEOs is the magic number at Bridgewater Associates

Miles

Leave a Comment

SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.

    100% secure your website.